Hennion & Walsh Asset Management Inc. Has $1.86 Million Stock Position in Immunocore Holdings plc (NASDAQ:IMCR)

Hennion & Walsh Asset Management Inc. lifted its stake in shares of Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 26.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 62,555 shares of the company's stock after acquiring an additional 12,947 shares during the period. Hennion & Walsh Asset Management Inc. owned 0.13% of Immunocore worth $1,856,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. lifted its position in shares of Immunocore by 3.1% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 6,700,208 shares of the company's stock worth $197,657,000 after purchasing an additional 200,373 shares in the last quarter. Primecap Management Co. CA lifted its holdings in shares of Immunocore by 8.0% in the 4th quarter. Primecap Management Co. CA now owns 2,668,550 shares of the company's stock worth $78,722,000 after purchasing an additional 196,530 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Immunocore by 1.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,187,530 shares of the company's stock worth $64,533,000 after acquiring an additional 29,832 shares during the period. Tang Capital Management LLC increased its stake in shares of Immunocore by 40.7% in the fourth quarter. Tang Capital Management LLC now owns 1,555,600 shares of the company's stock valued at $45,890,000 after purchasing an additional 450,000 shares during the period. Finally, Groupama Asset Managment bought a new stake in Immunocore during the 4th quarter valued at $17,700,000. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Immunocore

In other Immunocore news, Director Bros. Advisors Lp Baker bought 807,338 shares of Immunocore stock in a transaction that occurred on Monday, March 17th. The stock was acquired at an average price of $29.72 per share, for a total transaction of $23,994,085.36. Following the completion of the acquisition, the director now owns 2,144,060 shares of the company's stock, valued at $63,721,463.20. This trade represents a 60.40% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 10.40% of the stock is owned by insiders.

Immunocore Trading Down 3.2%

Shares of IMCR stock traded down $1.18 on Monday, reaching $36.07. The company had a trading volume of 777,933 shares, compared to its average volume of 372,290. The stock has a market cap of $1.81 billion, a PE ratio of -37.97 and a beta of 0.83. The company has a 50-day moving average of $30.23 and a 200-day moving average of $30.17. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. Immunocore Holdings plc has a 12 month low of $23.15 and a 12 month high of $42.09.

Immunocore (NASDAQ:IMCR - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.45. The company had revenue of $125.13 million during the quarter, compared to analyst estimates of $108.82 million. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The firm's revenue was up 33.6% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.49) EPS. On average, equities analysts forecast that Immunocore Holdings plc will post -0.94 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on IMCR. Morgan Stanley reissued an "equal weight" rating and issued a $35.00 price objective on shares of Immunocore in a research note on Friday, March 7th. HC Wainwright reiterated a "buy" rating and issued a $100.00 price target on shares of Immunocore in a research report on Monday, June 2nd. Mizuho cut their price objective on Immunocore from $38.00 to $33.00 and set a "neutral" rating on the stock in a report on Monday, April 7th. Wall Street Zen cut shares of Immunocore from a "buy" rating to a "hold" rating in a report on Friday. Finally, Oppenheimer upped their price target on shares of Immunocore from $85.00 to $86.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Immunocore has a consensus rating of "Moderate Buy" and an average price target of $58.89.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.